Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
After months of misdiagnoses, Tom Heisler found answers at Mayo Clinic, where advanced renal pathology revealed IgG4-related disease and led to his recovery.
Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable region gene (IGHV) when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY.
In May 2019, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Mayo Clinic Laboratories is one of the few laboratories in the country to offer two special sequencing-based tests for bacteria in its catalog. The first test is designed to help protect patients by investigating potential outbreaks of a single bacterial species or by identifying recurrent infections in an individual patient. The second has the ability to detect DNA of any bacteria to help identify the cause of an infection.
Blacklegged ticks (also known as deer ticks) are turning up more frequently in Minnesota, and so are the diseases they carry. Bobbi Pritt, a parasitologist in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, weighs in on the issue.
This week's research roundup features a study on the joint association of mammographic density and polygenic risk score and how they contribute to the prediction of breast cancer.
Antibodies to aquaporin-4 and myelin oligodendrocyte glycoprotein (MOG) are recently described biomarkers seen in a subset of atypical optic neuritis which have revolutionized our understanding of the condition. In this “Hot Topic,” my colleague, Dr. John Chen, will review these advances and how they impact the clinical care of our patients with optic neuritis.
The standard test for the diagnosis of narcolepsy is the multiple sleep latency test (MSLT). The MSLT is a complex test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy.
Jeffrey Winters, M.D., Vice Chair of the Division of Transfusion Medicine in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, was recognized at the American Society for Apheresis Annual (ASFA) Meeting in Portland, Oregon on May 16. Dr. Winters received the Francis S. Morrison, M.D., Lecture Memorial Award.
This “Phlebotomy” webinar reviews: Having a medical procedure or a lab draw can be fearful for children. Even if it is their first time or they have had a bad past experience, there are ways to make these procedures easier for children.
The presence NTRK gene fusions is one of the eligibility requirements for the recently FDA-approved therapy Vitrakvi (larotrectinib), a therapy indicated in adult and pediatric patients with solid tumors regardless of the type of tumor. NTRK gene fusions have been described in many cancers at various frequencies including common cancers such as lung, thyroid, and colorectal cancers.
Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.